Pat Rayman

718 total citations
16 papers, 583 citations indexed

About

Pat Rayman is a scholar working on Oncology, Immunology and Cancer Research. According to data from OpenAlex, Pat Rayman has authored 16 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Immunology and 4 papers in Cancer Research. Recurrent topics in Pat Rayman's work include Cancer Immunotherapy and Biomarkers (8 papers), Immune cells in cancer (6 papers) and Immune Cell Function and Interaction (3 papers). Pat Rayman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Immune cells in cancer (6 papers) and Immune Cell Function and Interaction (3 papers). Pat Rayman collaborates with scholars based in United States and United Kingdom. Pat Rayman's co-authors include James H. Finke, Jennifer S. Ko, Peter A. Cohen, Brian I. Rini, Joanna Ireland, Daniel J. Lindner, J. H. Finke, Edward A. Fisher, Denise A. Hatala and Zeneng Wang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Pat Rayman

15 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pat Rayman United States 8 253 249 193 192 116 16 583
Adeline Duc France 13 178 0.7× 352 1.4× 246 1.3× 317 1.7× 173 1.5× 18 775
Liye Ma China 15 231 0.9× 257 1.0× 159 0.8× 331 1.7× 157 1.4× 28 742
Gou Watanabe Japan 11 124 0.5× 306 1.2× 123 0.6× 201 1.0× 67 0.6× 25 596
Jian‐Yang Ao China 13 202 0.8× 179 0.7× 234 1.2× 328 1.7× 79 0.7× 25 665
Julien Lesage France 5 146 0.6× 227 0.9× 173 0.9× 255 1.3× 135 1.2× 6 576
Wei Geng China 9 231 0.9× 162 0.7× 121 0.6× 213 1.1× 188 1.6× 26 604
Subreen A. Khatib United States 12 126 0.5× 243 1.0× 265 1.4× 335 1.7× 101 0.9× 18 648
Ana M. Gil‐Bernabé United Kingdom 4 219 0.9× 293 1.2× 134 0.7× 213 1.1× 81 0.7× 5 607
Alessandro Villanucci Italy 14 113 0.4× 209 0.8× 110 0.6× 189 1.0× 128 1.1× 35 696
K. Myers United States 7 289 1.1× 175 0.7× 72 0.4× 209 1.1× 97 0.8× 12 541

Countries citing papers authored by Pat Rayman

Since Specialization
Citations

This map shows the geographic impact of Pat Rayman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pat Rayman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pat Rayman more than expected).

Fields of papers citing papers by Pat Rayman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pat Rayman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pat Rayman. The network helps show where Pat Rayman may publish in the future.

Co-authorship network of co-authors of Pat Rayman

This figure shows the co-authorship network connecting the top 25 collaborators of Pat Rayman. A scholar is included among the top collaborators of Pat Rayman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pat Rayman. Pat Rayman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ornstein, Moshe Chaim, Wei Wei, C. Marcela Díaz‐Montero, et al.. (2024). Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab. Clinical Genitourinary Cancer. 22(6). 102181–102181.
2.
Anand, Sanjay, Alan Shen, Jennifer Powers, et al.. (2024). Combination of vitamin D and photodynamic therapy enhances immune responses in murine models of squamous cell skin cancer. Photodiagnosis and Photodynamic Therapy. 45. 103983–103983. 8 indexed citations
3.
Ahluwalia, Manmeet S., David M. Peereboom, Ahmad Ozair, et al.. (2024). A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).. Journal of Clinical Oncology. 42(16_suppl). 2072–2072. 4 indexed citations
4.
Ford, Jill, Marieli Gonzalez-Cotto, Alexander W. Macfarlane, et al.. (2022). Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma. Frontiers in Oncology. 11. 662723–662723. 30 indexed citations
5.
Rayman, Pat, et al.. (2022). Immune Checkpoint Inhibitors (ICI) Promote Neutrophil-Platelet Aggregate and NET Formation in Tumor-Bearing Mice. Blood. 140(Supplement 1). 8365–8366. 4 indexed citations
6.
Soler, David, Amber Kerstetter-Fogle, A. B. Young, et al.. (2021). Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2). Molecular Immunology. 142. 1–10. 6 indexed citations
7.
Haywood, Samuel, Paul G. Pavicic, Lin Lin, et al.. (2016). Sunitinib's effect on tumor infiltration of CD8 T cells in renal cell carcinoma (RCC) and modulation of their function by altering VEGF-induced upregulation of PD1 expression.. Journal of Clinical Oncology. 34(2_suppl). 591–591. 4 indexed citations
8.
Zamanian-Daryoush, Maryam, Daniel J. Lindner, Thomas C. Tallant, et al.. (2013). The Cardioprotective Protein Apolipoprotein A1 Promotes Potent Anti-tumorigenic Effects. Journal of Biological Chemistry. 288(29). 21237–21252. 198 indexed citations
9.
Finke, James H., Pat Rayman, Jennifer S. Ko, et al.. (2013). Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics. The Cancer Journal. 19(4). 353–364. 41 indexed citations
10.
Khurana, Kiranpreet, Pat Rayman, Paul Elson, Brian I. Rini, & James H. Finke. (2013). Effect of pazopanib on myeloid-derived suppressor cells and T-cell function in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 31(6_suppl). 455–455. 1 indexed citations
11.
Smith, Kerri M., Tianyi M. Krupka, Bryan M. Wittmann, et al.. (2012). Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis. Oncogene. 32(33). 3829–3839. 29 indexed citations
12.
Finke, James H., Jennifer S. Ko, Brian I. Rini, et al.. (2011). MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. International Immunopharmacology. 11(7). 856–861. 226 indexed citations
13.
Ford, Jill, O. M. Zack Howard, Jeff Subleski, et al.. (2010). Enhanced Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and Soluble TREM-1 Levels in the Myeloid Cells of Tumor-Bearing Mice and Patients with Renal Cell Carcinoma (100.8). The Journal of Immunology. 184(Supplement_1). 100.8–100.8. 1 indexed citations
14.
Borden, Ernest C., Pat Rayman, Bénédikt Jacobs, et al.. (2010). Dual mechanistic function of MDSC subsets in melanoma resistance.. Journal of Clinical Oncology. 28(15_suppl). 8590–8590. 2 indexed citations
15.
Moltó, Luis, Pat Rayman, Ewa Paszkiewicz‐Kozik, et al.. (2003). The Bcl-2 transgene protects T cells from renal cell carcinoma-mediated apoptosis.. PubMed. 9(11). 4060–8. 15 indexed citations
16.
Wang, Qiu, O. Fernández Hidalgo, Pat Rayman, et al.. (1995). Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-hodgkin's lymphomas. Cancer Immunology Immunotherapy. 41(3). 175–184. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adeline Duc Breakdown of academic impact, for papers by Liye Ma Breakdown of academic impact, for papers by Gou Watanabe Breakdown of academic impact, for papers by Jian‐Yang Ao Breakdown of academic impact, for papers by Julien Lesage Breakdown of academic impact, for papers by Wei Geng Breakdown of academic impact, for papers by Subreen A. Khatib Breakdown of academic impact, for papers by Ana M. Gil‐Bernabé Breakdown of academic impact, for papers by Alessandro Villanucci Breakdown of academic impact, for papers by K. Myers
Rankless by CCL
2026